文献速递临床试验与 GCP真实世界研究与卫生经济

每日电子患者报告结局日记在类风湿关节炎随机对照试验中的应用:理由与实施

Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation.
PubMed 文献 · Trials · 2019-03-22

该文介绍在巴瑞替尼治疗的RA-BEAM和RA-BUILD两项3期随机对照试验中实施每日电子患者报告结局(ePRO)日记的方法。患者使用手持设备记录晨僵持续时间与严重程度、最严重疲劳感和最严重关节疼痛,至第12周平均依从性高(RA-BEAM 94%患者;RA-BUILD 93%患者),作者认为高依从性支持在大型随机对照试验中使用每日电子PRO日记。

要点

  • 在RA-BEAM和RA-BUILD两项3期随机对照试验中,患者使用手持设备每日记录ePRO。
  • 至第12周平均依从性高:RA-BEAM为94%患者,RA-BUILD为93%患者。
  • 识别的流程挑战包括设备发放不及时、电池电量低、患者培训不足等。

核心结论

  • 高依从性支持在大型随机对照试验中使用每日电子PRO日记。
  • 尽管存在预期问题,每日电子日记有望减少回忆偏倚并改善PRO数据收集质量。

研究设计与样本

  • 基于巴瑞替尼RA-BEAM和RA-BUILD两项3期随机对照试验,评估ePRO措施的实施情况。
  • 使用手持设备(Invivodata®,Inc.)每日采集PRO数据,设置三个报告窗口选项并编程闹钟。
  • RA-BEAM研究N=1305,RA-BUILD研究N=684,患者为中重度活动性类风湿关节炎。
  • 患者和中心工作人员接受每日电子日记使用培训。

主要发现

  • 至第12周平均依从性(完成天数/应完成天数)高:RA-BEAM 94%患者,RA-BUILD 93%患者。
  • 晨僵持续时间以「小时和分钟」记录。
  • 晨僵严重程度、最严重疲劳感和最严重关节疼痛采用0至10评分,评分越高症状越重。
  • 识别的流程挑战包括设备发放不及时、电池电量低、数据收集前患者培训不足、日记设置不当、基线访视后1天才首次录入。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文报告了识别的流程挑战,包括设备发放不及时、电池电量低、数据收集前患者培训不足、日记设置不当、基线访视后1天才首次录入。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rheumatoid arthritis (RA) is associated with significantly diminished health-related quality of life. Patient-reported outcomes (PROs) are considered important in RA; however, some symptoms such as morning joint stiffness (MJS) and fatigue that are considered important by patients are not captured by the American College of Rheumatology "core set" measures for RA trials. The US Food and Drug Administration has endorsed electronic capture of clinical trial data including PROs, and electronic PRO (ePRO) systems may lead to more accurate and complete data capture, improved compliance, and patient acceptance compared with paper-based methods. Our objective was to assess the implementation of ePRO measures of Duration and Severity of MJS, Severity of Worst Tiredness, and Severity of Worst Joint Pain in baricitinib RA-BEAM and RA-BUILD phase 3 randomized clinical trials (RCTs). METHODS: A daily electronic diary (handheld device; Invivodata®, Inc.) was utilized to capture PRO data in the RCTs. Three "reporting window" options were incorporated to accommodate differences in patients' routine daily schedules, and alarms were programmed for each reporting window. Duration of MJS was recorded in "hours and minutes," and Severity of MJS, Worst Tiredness, and Worst Joint Pain were captured on a 0 to 10 rating scale, with a higher score indicating more severe symptoms. The patients and site staff were trained to use the daily electronic diary. RESULTS: Patients with moderately to severely active RA used the daily electronic diary in the RA-BEAM study (N = 1305) and RA-BUILD study (N = 684). The average compliance, calculated as total days completed by patients compared with total days expected to complete the diary, through Week 12 was high (RA-BEAM 94% patients; RA-BUILD 93% patients), potentially attributable to appropriate training, clarity of instructions, simple user interface, and electronic device design. Identified process challenges included non-timely issuance of the device, low battery, inadequate training of patients before data collection, inappropriate diary set-up, and first response entry 1 day after the baseline visit. CONCLUSIONS: High compliance rates support the use of the daily electronic PRO diary in large RCTs. Despite the anticipated issues, the daily electronic diary is expected to reduce recall bias and improve the quality of PRO data collection. TRIAL REGISTRATION: RA-BEAM ( NCT01710358 ) and RA-BUILD ( NCT01721057 ).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Bingham CO, Gaich CL, DeLozier AM, et al. Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation. Trials. 2019. PMID: 30902094. doi:10.1186/s13063-019-3272-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。